Pantop%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. It is available for oral and intravenous administration. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD) * Maintenance of healing of erosive esophagitis * Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome) ## Adult Dosing * **Erosive esophagitis:** 40 mg orally once daily for up to 8 weeks. * **Maintenance of healing:** 40 mg orally once daily. * **Pathological hypersecretory conditions:** 40 mg orally twice daily, may be increased to a maximum of 80 mg twice daily. * **Intravenous (IV):** 40 mg IV once daily. For pathological hypersecretory conditions, may be increased to 80 mg IV once daily. ## Pediatric Dosing Dosing in pediatric patients is variable and depends on age and indication. Consult specific pediatric guidelines. * **Children 5 to 11 years:** * Erosive esophagitis: 20-40 mg orally once daily. * **Adolescents 12 to 17 years:** * Erosive esophagitis: 40 mg orally once daily. ## Dose Adjustments No dose adjustment is generally required for hepatic or renal impairment, though caution is advised in severe hepatic impairment. ## Contraindications * Known hypersensitivity to pantoprazole or any component of the formulation. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term use may be associated with an increased risk of bone fractures, Clostridium difficile infection, and vitamin B12 deficiency. ## Key Drug Interactions * **Drugs requiring gastric acid for absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, and certain HIV protease inhibitors. * **Methotrexate:** PPIs may increase methotrexate levels; consider temporary pantoprazole discontinuation if methotrexate is used at high doses. * **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Consider potential interactions with drugs like clopidogrel (though clinical significance is debated). ## Monitoring * Monitor for signs and symptoms of fracture, C. difficile infection, and B12 deficiency with long-term therapy. * Assess symptom relief and healing of esophagitis. ## Clinical Pearls * Administer oral pantoprazole 30-60 minutes before a meal for optimal efficacy. * IV pantoprazole can be administered as a slow injection or infusion. * Consider the risks of long-term PPI use when prescribing for extended durations. *** *This information is intended for healthcare professionals. Always consult the current prescribing information and relevant clinical guidelines for complete details before making any treatment decisions.*